If your peptide is an active pharmaceutical ingredient, ICH Q7 is the guideline that defines how it must be manufactured under GMP. Understanding its expectations early prevents painful surprises during inspection or filing.
What is ICH Q7?
ICH Q7 is the internationally harmonised Good Manufacturing Practice guide for active pharmaceutical ingredients (APIs). It sets the GMP expectations that a peptide API manufacturer must meet — from quality management and personnel to process controls, validation and documentation. It is a cornerstone of the framework summarised in our GMP & quality guide.
What ICH Q7 covers
- Quality management: defined responsibilities and a functioning quality unit.
- Process controls: in-process controls and defined critical parameters.
- Validation: process and cleaning validation appropriate to the API.
- Materials & suppliers: qualification and control of raw materials.
- Documentation: batch records, change control and deviation handling.
- Stability & storage: data to support retest or expiry dating.
Where the API process begins
A practical Q7 question for peptides is defining the point at which GMP “starts” in the process. Q7 expects increasing GMP rigor as you approach the final API, with that starting point justified and documented. Getting this right avoids both over- and under-control.
Key point: Q7 is about demonstrable control and documentation. Inspectors look for evidence that your process does what you say it does, consistently — and that you can prove it.
What it means in practice
For peptide manufacturers, Q7 translates into validated processes, qualified materials, controlled batch records, validated analytical methods, and robust change and deviation management. It underpins the CMC story you tell in a filing — see writing the CMC section for a peptide IND.